Meeting
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
Authors
Manmeet Singh Ahluwalia
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH
Manmeet Singh Ahluwalia , Yasmeen Rauf , Hong Li , Patrick Y. Wen , David M. Peereboom , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03452579
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2015)
DOI
10.1200/JCO.2021.39.15_suppl.2015
Abstract #
2015
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
First Author: Jaleh Fallah
Poster
2015 ASCO Annual Meeting
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
First Author: Ashley Ghiaseddin
Poster
2023 ASCO Annual Meeting
Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).
First Author: John Yohan Rhee
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen